CADTH | Evidence Driven
CADTH | Evidence Driven

Adcetris for Hodgkin’s Lymphoma (post-ASCT) Resubmission – Details

Details

Files
Generic Name:
Brentuximab Vedotin
Project Status:
Complete
Therapeutic Area:
HL at high risk of relapse or progression post-ASCT
Manufacturer:
Seattle Genetics, Inc.
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0116-000
NOC Status at Filing:
Post NOC
Strength:
50 mg
Tumour Type:
Lymphoma
Indications:
Hodgkin’s Lymphoma at high risk of relapse or progression post-ASCT
Funding Request:
Funding for ADCETRIS is requested for post-ASCT consolidation treatment of patients with HL at increased risk* of relapse or progression. *The definition of high risk of post-ASCT relapse or progression based on the AETHERA trial are: refractory to frontline therapy, relapsed <12 months following frontline therapy, or relapsed >12 months with extranodal involvement.
Sponsor:
Seattle Genetics, Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation:

Files

Provincial Funding Summary View PDF
Brentuximab (Adcetris) HL (post-ASCT) Resubmission – pERC Final Recommendation Final Recommendation February 21, 2018 View PDF
Brentuximab (Adcetris) HL (post-ASCT) Resubmission – Final Clinical Guidance Report Guidance Reports February 21, 2018 View PDF
Brentuximab (Adcetris) HL (post-ASCT) Resubmission – Final Economic Guidance Report Guidance Reports February 21, 2018 View PDF
Brentuximab (Adcetris) HL (post-ASCT) Resubmission – pERC Initial Recommendation Initial Recommendation February 1, 2018 View PDF
Brentuximab (Adcetris) HL (post-ASCT) Resubmission – PAG Feedback on Initial Recommendation Feedback February 21, 2018 View PDF
Brentuximab (Adcetris) HL (post-ASCT) Resubmission – Manufacturer Feedback on Initial Recommendation Feedback February 21, 2018 View PDF
Brentuximab (Adcetris) HL (post-ASCT) Resubmission – Clinician Feedback on Initial Recommendation Feedback February 21, 2018 View PDF
Brentuximab (Adcetris) HL (post-ASCT) Resubmission – Patient Group COI Declarations COI Declarations February 21, 2018 View PDF
Brentuximab (Adcetris) HL (post-ASCT) Resubmission – Clinician COI Declarations COI Declarations February 21, 2018 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : March 8, 2018